27.05.2019 11:31, Joseph Heaven
The startup's assay detects cancer-related genomic instability for a faster, earlier diagnosis. With his patented medical test on the cusp of U.S.- and EU-regulatory approval, 4D's founder Arne Christian Faisst visits Boston seeking a $9 Million C-round to accelerate market entry.
What medical need does problem does 4D Lifetec serve?
Cancer is the second leading cause of death. People are usually only diagnosed late, once the primary tumour has become symptomatic and multiplied many times throughout the body. Our liquid biopsy assay detects cancer earlier, when it is still asymptomatic, so patients can get better treatment. 4D Lifetest™, our general tumour biomarker, has outstanding potential as a fast and cost-effective diagnostic verification assay for various types of cancers.
What are your goals for the roadshows in Boston with Venture Leaders Life Sciences?
We're looking to raise $9 million. We've started clinical testing and market entry in Europe, so want to find investors able to financing U.S. market entry. Boston is the ideal place to meet the strategic partners and key opinion leaders. I want to learn more about U.S.-specific requirements, and build the network to make market entry as fast as possible.
How will Venture Leaders Life Sciences benefit your startup?
Venture Leaders Life Sciences gives us visibility and opens doors to the U.S. biotech world. The program offers me the chance to exchange with industry peers at similar stages of their entrepreneurial journey.
Venture Leaders Life Sciences is sponsored by Rothschild & Co Bank, Kellerhals Carrard, swissnex Boston, Ypsomed, Paul Schererr Institute, Canton de Vaud, EPF Lausanne and ETH Zürich.